Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
4Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
Decoy Therapeutics Inc. (DCOY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
2Distinct source URLs
5High confidence
0.776Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Decoy Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
CPRIT
CPRIT
90%
The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract
UNIVERSITY-OF-UTAH-RESEARCH-FOUNDATION
UNIVERSITY-OF-UTAH-RESEARCH-FOUNDATION
90%
The Company entered into a license agreement with the University of Utah, under which, the Company acquired license to LSD 1
Decoy Therapeutics Inc. Customers
Ticker
Name
Confidence
Evidence
APTAR-PHARMA-INC
APTAR-PHARMA-INC
62%
on inhibitor, including: • Pre- and post-exposure prophylaxis (“PrEP”/”PEP”) for highly immunocompromised populations facing elevated risks from severe immune deficiencies associated with hematologic…
SALARIUS-PHARMACEUTICALS-INC
SALARIUS-PHARMACEUTICALS-INC
62%
stock and additional paid-in capital amounts have been recast to reflect the 1-for-8, 1-for-15 and 1-for-12 reverse stock splits effected on June 14, 2024, August 15, 2025 and March 6, 2026, respecti…
SALARIUS-PHARMACEUTICALS-LLC-FLEX-INNOVATION-GRO
SALARIUS-PHARMACEUTICALS-LLC-FLEX-INNOVATION-GRO
62%
stock and additional paid-in capital amounts have been recast to reflect the 1-for-8, 1-for-15 and 1-for-12 reverse stock splits effected on June 14, 2024, August 15, 2025 and March 6, 2026, respecti…
TK-PHARMA-INC
TK-PHARMA-INC
62%
stock and additional paid-in capital amounts have been recast to reflect the 1-for-8, 1-for-15 and 1-for-12 reverse stock splits effected on June 14, 2024, August 15, 2025 and March 6, 2026, respecti…
Decoy Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
DCOY-DEBT-9040
Warrants outstanding: 142711
90%
xbrl warrant detail from xbrl 2025-12-31.
DCOY-DEBT-9041
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
Decoy Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Decoy Therapeutics Inc..
Decoy Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
DCOY-OWNER-WARBERG-ASSET-MANAGEMENT-LLC
Warberg Asset Management LLC
90%
13F overlay lists Warberg Asset Management LLC as top holder; 9 tracked holders.
Decoy Therapeutics Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
